KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $78.8 million.

  • Halozyme Therapeutics' Cost of Revenue rose 8730.23% to $78.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $228.8 million, marking a year-over-year increase of 4350.67%. This contributed to the annual value of $228.8 million for FY2025, which is 4350.67% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Cost of Revenue stood at $78.8 million, which was up 8730.23% from $55.2 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Cost of Revenue high stood at $78.8 million for Q4 2025, and its period low was $15.9 million during Q1 2022.
  • Its 5-year average for Cost of Revenue is $40.1 million, with a median of $42.1 million in 2022.
  • In the last 5 years, Halozyme Therapeutics' Cost of Revenue soared by 30101.05% in 2021 and then crashed by 2089.67% in 2024.
  • Halozyme Therapeutics' Cost of Revenue (Quarter) stood at $21.6 million in 2021, then surged by 95.12% to $42.1 million in 2022, then grew by 24.16% to $52.3 million in 2023, then fell by 19.59% to $42.1 million in 2024, then soared by 87.3% to $78.8 million in 2025.
  • Its Cost of Revenue stands at $78.8 million for Q4 2025, versus $55.2 million for Q3 2025 and $46.4 million for Q2 2025.